#United States #CTXR #Cranford #Citius Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Closes $15.8 Million Offering

Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a leading biopharmaceutical firm focused on developing innovative critical care products, has announced the successful closure of its registered direct offering. This strategic move is aimed at bolstering support for the commercial launch of its newly approved immunotherapy, LYMPHIR™, which is indicated for the treatment of cutaneous T-cell lymphoma.

On June 12, 2025, the company confirmed the completion of an offering that generated gross proceeds of approximately $6 million, before deducting fees and expenses incurred during the process. Investors have the potential to add up to $9.8 million more through the exercise of short-term warrants associated with the offering.

The offering consisted of 4,920,000 shares of common stock, priced at $1.22 each, alongside warrants to purchase an aggregate of 9,840,000 shares. These short-term warrants, which can be exercised immediately at a price of $1.00 per share, will expire 24 months from their issuance date. The exclusive placement agent for this offering was H.C. Wainwright & Co., a recognized entity in the sector.

The net proceeds from this offering are intended to be utilized for multiple purposes. A significant portion will support the commercial launch of LYMPHIR™, including milestone and regulatory payments. Additionally, the funds will be directed towards general corporate purposes, effectively providing a robust financial backing for the company’s ongoing initiatives.

Citius Pharmaceuticals views LYMPHIR™ as a pivotal product in its portfolio. The U.S. Food and Drug Administration (FDA) approved the drug in August 2024, marking a significant milestone in the company's history and enabling it to cater to patients in urgent need of effective treatment options for cutaneous T-cell lymphoma.

Moreover, Citius Pharma's late-stage product pipeline includes other promising candidates such as Mino-Lok®, an antibiotic lock solution aimed at preserving catheters in patients battling catheter-related bloodstream infections. With a solid track record, Mino-Lok has successfully met both primary and secondary endpoints in its pivotal Phase 3 trial conducted in 2023, further solidifying the company’s position in the biopharmaceutical landscape.

Financial Overview and Future Directions

Initial cash flows from the offering significantly enhance Citius Pharma’s financial resources. Yet, the potential earnings from the short-term warrants remain contingent as the company cannot guarantee their full exercise. This uncertainty underscores the competitive nature of the biopharmaceutical market, where adequate funding is paramount for continued research and development, product commercialization, and overall company stability.

The strategic decisions surrounding the allocation of funds from the offering indicate Citius Pharma’s commitment to not just immediate financial health but also long-term growth. By fortifying its commercial launch efforts and investing in pipeline expansions, Citius Pharmaceuticals demonstrates a proactive approach in an increasingly challenging healthcare environment.

Conclusion

Citius Pharmaceuticals stands at a crucial point as it advances towards launching LYMPHIR™ and continues developing other therapeutic solutions. As the company strives to make meaningful impacts on patient care, it will rely heavily on its funding strategies, innovative approach to drug development, and a dedicated team focused on addressing pressing healthcare challenges. Investors and stakeholders will be closely monitoring the company's next steps as it navigates this exciting phase of growth and opportunity.